By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...

The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...

Novavax Inc. said this week that its COVID-19 vaccine would not receive regulatory clearance in the U.S. or the U.K. until at least July, while a shortage of materials has delayed its production ...

The mRNA vaccines work by prompting the body to temporarily make its own spike protein, which the immune system then responds to, generating protective antibodies and other immune cells. For the ...

Shah Capital is reportedly pressing Novavax Inc. (NASDAQ:NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine. • NVAX stock is showing ...

Jan 20 (Reuters) - Novavax ‌said on Tuesday it signed a licensing ‌agreement allowing Pfizer access to its technology that boosts immune responses to vaccines for use in up to two infectious diseases, ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later, the ...